Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
Condition(s):Amyotrophic Lateral SclerosisLast Updated:March 9, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Amyotrophic Lateral SclerosisLast Updated:March 9, 2023Terminated
Condition(s):ContraceptionLast Updated:May 12, 2015Completed
Condition(s):HemodynamicsLast Updated:March 7, 2019Unknown status
Condition(s):Ischemic Heart Disease; Valvular Heart DiseaseLast Updated:January 19, 2024Recruiting
Condition(s):Systolic Heart FailureLast Updated:December 5, 2018Unknown status
Condition(s):ST Elevation Myocardial InfarctionLast Updated:February 11, 2021Unknown status
Condition(s):Left Ventricular Dysfunction; Right Ventricular Dysfunction; Biventricular FailureLast Updated:April 3, 2020Unknown status
Condition(s):Hypertension Pulmonary Secondary Heart Failure; Right Sided Heart Failure With Normal Ejection Fraction; Heart Failure With Normal Ejection FractionLast Updated:April 30, 2021Unknown status
Condition(s):Mitral Valve Replacement; Pulmonary Hypertension; Inhaled Milrinone; Intravenous MilrinoneLast Updated:March 13, 2024Active, not recruiting
Condition(s):Heart FailureLast Updated:July 17, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.